Pfizer is an American multinational pharmaceutical and biotechnology corporation headquartered in New York City. Founded in 1849, it develops and manufactures medicines and vaccines across multiple therapeutic areas.
Pfizer reported positive Phase II data for PF-07872412, a 25-valent pneumococcal conjugate vaccine candidate in infants. Serotype 3 geometric mean titers were 8.8-fold higher after dose three and about 15-fold higher after dose four versus PREVNAR 20.
The European Commission expanded Hympavzi approval to patients 12 and older with hemophilia A or B with inhibitors. Phase 3 data showed a 93% reduction in mean treated annualized bleeding rate versus on-demand therapy.
Trump secured agreements with 16 pharmaceutical companies tied to TrumpRx.gov, including most-favoured-nation pricing and direct-to-patient discounts. Several companies disclosed price cuts for obesity, diabetes, insulin and other medicines.
Guardant Health said its chief medical officer will resign effective May 8, while Delfi Diagnostics appointed Charles Newton to its board and Singular Genomics named John Stark CEO.
Pfizer reported new clinical and regulatory milestones across oncology, obesity and hemophilia, including BREAKWATER Phase 3 data and Priority Review for HYMPAVZI. The company also cited MagnetisMM-5 results and FDA priority review for PADCEV.
FDA has accepted the NDA for vepdegestrant (ARV-471), an oral PROTAC ER degrader from Arvinas and Pfizer, for ESR1-mutated ER+/HER2- advanced breast cancer. A PDUFA date of June 5, 2026 has been set. The submission is based on positive Phase 3 VERITAC-2 data.
European biotechs are exploring new immunotherapy targets beyond PD-1/PD-L1, including BTLA, TIGIT, and SLAMF6. Lund University researchers discovered a SLAMF6-mediated immune evasion mechanism. BioNTech and GenMab are advancing next-generation ICIs and bispecific antibodies through strategic partnerships.
Recent biosimilar and biologic developments included Health Canada approval of denosumab biosimilars, FDA review actions, and new licensing and commercialisation agreements. Other updates covered court, trial and reimbursement agenda decisions.
BioNTech enters May with first-quarter earnings due May 5 and a May 15 shareholder vote on a capital increase. The company is pushing its oncology pipeline as COVID-19 vaccine sales decline.
Eli Lilly, AbbVie, Vertex, Gilead Sciences and Pfizer were identified as pharmaceutical stocks to watch, with Abbott Laboratories and McKesson appearing on a separate seven-stock list.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07597928 |
A Study to Learn How Different Forms of the Study Medicine Called PF-08049820 Are Absorbed and Eliminated in Healthy Adults |
NOT_YET_RECRUITING | PHASE1 |
| NCT07595549 |
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity |
NOT_YET_RECRUITING | PHASE3 |
| NCT07594769 |
A Study to Compare the Blood Levels of Two Dosage Formulations of the Study Medicine in Healthy Adults |
NOT_YET_RECRUITING | PHASE1 |
| NCT07592910 |
A Study of Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor Therapy |
NOT_YET_RECRUITING | PHASE2 |
| NCT07587697 |
A Study to Compare the Amount of Two Forms of Tafamidis in the Blood of Healthy Adults Under Fasting Conditions |
RECRUITING | PHASE1 |
| NCT07578649 |
Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer |
NOT_YET_RECRUITING | PHASE3 |
| NCT07578636 |
A Study to Understand What the Body Does to the Study Medicine Called PF-07799544 When Taken by Healthy Adults |
NOT_YET_RECRUITING | PHASE1 |
| NCT07575945 |
A Study to Learn if a Medicine Called Itraconazole Changes How the Body Processes the Study Medicine PF-08642534 in Healthy Adults. |
NOT_YET_RECRUITING | PHASE1 |
| NCT07575932 |
A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1) |
NOT_YET_RECRUITING | PHASE2 |
| NCT07575906 |
A Study to Learn How a Single Dose of the Study Medicine Called PF-08057418 is Tolerated in the Body of Healthy Adults. |
NOT_YET_RECRUITING | PHASE1 |
